

Henry A. Nasrallah, MD Editor-in-Chief

Might it resolve to spend far more money on innovative research and development than on marketing?

## What if ... A drug company's New Year's resolutions

Making New Year's resolutions is a time-honored tradition. Whether we resolve to lose a few pounds, exercise regularly, or quit a harmful habit, we all partake in self-improvement as the new year dawns. What would a large corporation resolve to do in the new year? We can only imagine, but a corporation that discovers and manufactures CNS pharmaceuticals might resolve to:

- 1. Test new drugs in patients who resemble "real world" patients, not just in patients with no medical problems, no substance abuse, and no history of treatment resistance.
- **2. Develop drugs** with new mechanisms, not just another "me too" agent.
- 3. Publish all data (positive and negative), not just favorable results.
- 4. Develop drugs for children, rather than following the tradition of developing drugs for adults and then waiting many years (during which practitioners use those drugs off-label in children) before finally conducting trials to secure FDA approval of pediatric indications.
- **5. Conduct studies** to guide practitioners about the safety of new drugs in pregnant women with mental illness.
- **6. Spend far more money** on innovative research and development than on marketing.
- 7. Kick the habit of direct-to-consumer marketing, so that physicians can prescribe the best agent in their clinical judgment, not the drug the patient demands because she saw it on TV.
- **8.** Accelerate the discovery of pharmacogenomic biomarkers to help match drug and patient, maximize efficacy, and minimize serious side effects.
- 9. Be more transparent about the fact that many clinical trials are being conducted in developing countries because U.S.-based trials have become too expensive and pose other "disadvantages" (such as a higher placebo response rate and more side effect complaints).
- 10. Establish mutually beneficial partnerships with the National Institutes



## From the **Editor**

- of Health and academic research institutes to translate neurobiological discoveries into new and physiologydriven pharmacotherapeutic interventions.
- 11. Pool grants with competitors so that continuing medical education (CME) programs are no longer sponsored by a single company and are designed without real or perceived influence by an industry sponsor.
- 12. Better inform the public about the pharmaceutical industry's positive aspects, such as being the only U.S. industry that: a) develops new medications for disabling psychiatric disorders; b) donates billions of dollars worth of drug samples to indigent or uninsured community patients; and c) provides hundreds of thousands of well-paying jobs for scientists, managers, and sales representatives.
- 13. Remind the world that hundreds of disabling and fatal diseases still have no available treatments, and a huge financial investment and years of basic and clinic research are needed to discover the needed treatments for them.

- **14. Justify the high cost** of new drugs by demonstrating how profits are ploughed into discovering new drugs (in other words, show convincingly that the pharmaceutical industry works for the public good, not just for shareholders).
- **15. Stop buying lunches** for doctors who attend speaker programs, and instead make donations to their designated charities.

I cannot vouch that this fictional account of a pharmaceutical company's New Year's resolutions reflects reality. But if it does, I wonder if such resolutions—like those of almost all of us—would falter soon after the new year starts....

Hong A. Nanallalu

Henry A. Nasrallah, MD Editor-in-Chief

